PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|July 23, 2013
Maurizio Denaro Named General Manager of The Aptuit Center for Discovery & Development
Author(s)Pharmaceutical Technology Editors
Aptuit has announced that Maurizio Denaro has assumed responsibilities as general manager of The Aptuit Center for Discovery & Development in Verona, Italy.
Advertisement
Aptuit has announced that Maurizio Denaro has assumed responsibilities as general manager of The Aptuit Center for Discovery & Development in Verona, Italy.
Denaro's career has included corporate and R&D leadership roles at global life science companies in both Europe and the United States, including Bracco Imaging, where he was responsible for the ultrasound business unit, Marion Merrell Dow, OSI Pharmaceuticals, Amylin Pharmaceuticals, and Hoechst Marion Roussel.
After earning a degree in Medicine from the University of Bologna, Italy, Denaro continued his post-doctoral studies in the United States at Stanford Medical School's Department of Genetics and as a senior researcher at the Wallenburg Laboratory, Uppsala University, Sweden. He then became a research associate in Experimental Oncology at the Centro di Riferimento Oncologico in Aviano, Italy. Denaro is credited with the filing of 19 patents and his findings have appeared in 59 publications.
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
4
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
5